Novo Nordisk's Midyear Report: A Pipeline Setback Meets the Oral Wegovy Question

Novo Nordisk reports H1 results amid 25% stock drop, ZEUS trial failure, and hopes pinned on oral Wegovy to counter Eli Lilly's lead.

The Danish pharmaceutical giant steps into the earnings spotlight on Wednesday with more than just quarterly numbers riding on the outcome. When Novo Nordisk releases its first-half results before the European market opens on August 5, 2026, investors will be looking for evidence that the company's growth engine — the oral version of Wegovy — can offset a bruising stretch that has knocked more than a quarter off the share price since January.

The Numbers on the Table

Consensus estimates put earnings at $0.77 per share on revenue of roughly $10.88 billion. That would mark a notable step down from the previous quarter, when the company delivered $1.03 per share on sales of $10.85 billion, supported by a net margin of 37.23 percent and a return on equity of 63.31 percent. The projected decline in profitability explains much of the market's current caution.

The shares closed Monday at €40.83, down 0.17 percent, after a week that saw the stock shed 8.56 percent. The monthly decline stands at 5.18 percent, and the year-to-date loss is 7.86 percent. From the January record high of €54.86, the stock now sits 25.57 percent lower — though it remains well above the 52-week trough of €30.25 touched in March.

A Stock Caught Between Two Averages

Perhaps the most telling technical signal is where the share price currently sits: almost exactly between the 50-day moving average of €40.95 and the 200-day average of €40.34. That narrow band reflects a market unwilling to commit to a direction until the company provides clearer guidance. The 30-day volatility reading of 34.19 percent underscores the tension, while the relative strength index at 41.5 points to neither oversold nor overbought conditions.

The secondary source notes the stock is hovering around €40.56, fighting to hold the 200-day line — a level that could prove decisive in the coming sessions.

The ZEUS Setback and Its Ripple Effects

The timing of this report could hardly be more challenging. Late July brought news that Ziltivekimab, the company's cardiovascular candidate, had failed to meet the primary endpoint in the Phase 3 ZEUS trial. The drug did not significantly reduce major adverse cardiovascular events compared with placebo, a result that immediately pressured the stock and raised questions about a pipeline that extends beyond the core obesity franchise.

That disappointment landed on top of intensifying competition in the weight-loss market. Eli Lilly has been steadily gaining ground, with industry data suggesting the rival now commands roughly 60 percent of certain US obesity-treatment segments. Novo Nordisk's current US market share stands at 39 percent, and defending that position has become increasingly difficult.

The Oral Pill as Counterweight

The bull case for the second half of 2026 rests largely on one product: the oral formulation of semaglutide. The Wegovy pill exceeded analyst expectations by a factor of two in the first quarter, and the question now is whether that momentum continued into the spring months. Unlike injectable competitors, the pill offers a primary-care-friendly alternative with little direct competition in its segment — a potential high-volume niche that sidesteps the complex manufacturing required for injection pens.

There are also signs of relief on the supply front. Novo Nordisk is integrating three Catalent fill-finish facilities in Italy, Belgium, and the United States, with additional capacity expected to come online from 2026. Confirmation that this expansion is ahead of schedule would go some way toward easing concerns about manufacturing bottlenecks that have historically constrained growth.

The Bear Case: Margins, Pricing, and Pipeline Depth

The more pessimistic reading centers on structural pressures that could persist well beyond this earnings cycle. Eli Lilly's pipeline continues to deliver impressive efficacy data — Retatrutide studies have shown weight loss of around 22.6 percent — and the company's aggressive pricing strategy, including products like Foundayo, keeps the pressure on. Should Lilly secure stronger international supply chains, Novo Nordisk's defensive position would weaken further.

US pricing dynamics add another layer of uncertainty. The industry is bracing for "price resets," and most-favored-nation-style arrangements could take effect from 2027. Novo Nordisk has already guided for a 5 to 13 percent decline in adjusted revenue at constant exchange rates for 2026. If the gap between gross and net sales widens more than anticipated in the half-year figures, the 200-day moving average could come under serious threat.

The pipeline concern is more fundamental. The ZEUS failure exposed a vulnerability: Novo Nordisk's deep specialization in metabolic disorders leaves it with fewer fallback options than more diversified rivals. Another setback in the GLP-1 core portfolio would hit disproportionately hard.

What Wednesday's Report Will Settle

The management's tone on August 5 will likely dictate the near-term trajectory. Holding above the 200-day average would suggest a stabilization phase, while reaffirming the full-year outlook alongside continued growth in oral Wegovy sales could push the stock back toward the 50-day line.

The risks are equally clear. A cut to the free cash flow guidance — currently set at DKK 35 to 45 billion for the year — or evidence of further share losses to Lilly could open the door to a test of the €35 level, with the 52-week low of €30.25 as a more distant but plausible target.

One additional factor deserves attention: the pace of the Catalent integration. Any delays there would cast a shadow over 2027 prospects and could extend the current weakness well into the next fiscal year. For now, the market's message is one of waiting — the shares are parked between their key moving averages, and Wednesday's numbers will determine which way they break.